In a report released today, Gaurav Goparaju from Berenberg Bank maintained a Buy rating on Certara (CERT – Research Report), with a price target of $19.00. The company’s shares opened today at $16.18.
According to TipRanks, Goparaju is an analyst with an average return of -20.8% and a 23.66% success rate. Goparaju covers the Healthcare sector, focusing on stocks such as Ginkgo Bioworks Holdings, Certara, and 23andMe Holding.
Certara has an analyst consensus of Moderate Buy, with a price target consensus of $19.29, representing a 19.22% upside. In a report released on August 15, Bank of America Securities also maintained a Buy rating on the stock with a $24.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $24.96 and a one-year low of $10.60. Currently, Certara has an average volume of 1.02M.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
Read More on CERT:
